Vir BiotechnologyVIR -0.15%51 PB Ratio is 1.97 as of Jun. 25, 2026, which is 19% above its 10-year median of 1.66. GuruFocus rates VIR with a GF Score™ of 51/100 and a GF Value™ of $20.33 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 1,233 Biotechnology companies, Vir Biotechnology ranks better than 63.58% on this metric.
Vir Biotechnology Inc stock PB Ratio (=1.97) is close to 3-year high of 2.13.
The historical rank and industry rank for Vir Biotechnology's PB Ratio or its related term are showing as below:
VIR'
s PB Ratio Range Over the Past 10 Years
Min: 0.6 Med: 1.66 Max: 13.61
Current: 1.97
During the past 9 years, Vir Biotechnology's highest PB Ratio was 13.61. The lowest was 0.60. And the median was 1.66.
VIR's PB Ratio is ranked better than 63.58% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs VIR: 1.97
During the past 12 months, Vir Biotechnology's average Book Value Per Share Growth Rate was -33.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -29.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -3.30% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Vir Biotechnology was 58.20% per year. The lowest was -29.40% per year. And the median was 9.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vir Biotechnology PB Ratio Related Terms
Vir Biotechnology PB Ratio Historical Data
* Premium members only.
The historical data trend for Vir Biotechnology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vir Biotechnology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vir Biotechnology (VIR) has a PB Ratio of 1.97 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vir Biotechnology and its competitors. This is 19% above median its historical median of 1.66. Over the past decade, Vir Biotechnology's PB Ratio has ranged from 0.60 to 13.61. According to the industry distribution chart, Vir Biotechnology ranks #449 out of 1233 companies in the Biotechnology industry, placing it in the top 36.4%.
Is Vir Biotechnology's PB Ratio too high?
Vir Biotechnology's current PB Ratio of 1.97 is 19% above median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 13.61. The Biotechnology industry median PB Ratio is 2.80. Vir Biotechnology's value of 1.97 is 29.6% below this industry median. Based on the distribution chart, Vir Biotechnology ranks #449 out of 1233 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vir Biotechnology has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's PB Ratio compare to ANAB and INVA?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #449 out of 1233 companies for PB Ratio. This puts Vir Biotechnology in the upper half of its industry. The industry median PB Ratio is 2.80. Vir Biotechnology's value of 1.97 is 29.6% below this benchmark. Historically, Vir Biotechnology's own PB Ratio has ranged from 0.60 to 13.61 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 2.80, Vir Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vir Biotechnology's current PB Ratio of 1.97 is 29.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vir Biotechnology and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vir Biotechnology's current PB Ratio is 1.97, which is 19% above median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Vir Biotechnology (VIR) is currently considered Possible Value Trap. The stock's GF Value™ is $20.33, compared to a current price of $9.94 — trading 51.1% below its estimated fair value. The current PB Ratio is 1.97, which is 19% above median its 10-year median of 1.66 and 29.6% below the Biotechnology industry median of 2.80. Vir Biotechnology's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vir Biotechnology (VIR), the current PB Ratio is 1.97 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of $9.94 is trading 51.1% below its estimated GF Value™ of $20.33.
GuruFocus considers Vir Biotechnology to be Possible Value Trap.
Key valuation signals for VIR:
PB Ratio: 1.97 (19% above median its 10-year median of 1.66)
GF Value™: $20.33 vs. price of $9.94 (51.1% below fair value)
Industry Position: 29.6% below the Biotechnology median (#449 of 1233)
No single metric tells the full story. See the VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
51GF Score
Get the complete analysis for VIR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIR has been successfully added to your 
